Comparative study of cefaclor and amoxicillin in treatment of urinary tract infection. 1979

J Rotschafer, and K Crossley, and D Zaske, and R Viste

Cefaclor or amoxicillin was given to 51 randomly assigned patients with urinary tract infections. Inclusion in the study required two pretreatment urine cultures yielding the same organism (susceptible to both antibiotics) in concentrations greater than or equal to 10(5)/ml. Both drugs were administered as 250 mg. orally every eight hours for ten days. Cefaclor was given to 27 patients and amoxicillin to 24. Most patients in both groups had negative urine cultures at five to nine days and four to six weeks following therapy. One patient in each group was unsuccessfully treated. Relapse or reinfection occurred with similar frequency in both treatment groups. Both antibiotics were well tolerated. minimal inhibiting concentrations (MICS) of cefaclor, amoxicillin, cephradine, and cephalexin were determined by an agar dilution technique for the 44 available pretreatment isolates (41 Escherichia coli and 3 Proteus mirabilis). Mean MICs (micrograms./ml., +/- SD) were 2.2 +/- 1.4 for cefaclor, 4.4 +/- 2.0 with amoxicillin, 8.1 +/- 4.2 for cephradine, and 5.7 +/- 3.0 with cephalexin. Cefaclor is highly active in vitro against those gram-negative bacteria which are commonly isolated from urine. Cefaclor is as effective as amoxicillin when administered three times daily for the treatment of urinary tract infection.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011512 Proteus Infections Infections with bacteria of the genus PROTEUS. Infections, Proteus,Infection, Proteus,Proteus Infection
D011513 Proteus mirabilis A species of gram-negative, facultatively anaerobic, rod-shaped bacteria that is frequently isolated from clinical specimens. Its most common site of infection is the urinary tract.
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D002433 Cefaclor Semisynthetic, broad-spectrum antibiotic derivative of CEPHALEXIN. 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-chloro-8-oxo-, (6R-(6alpha,7beta(R*)))-,Ceclor,Cefaclor Anhydrous,Cefaclor Monohydrate,Keclor,Lilly 99638,S-6472,S 6472,S6472
D002506 Cephalexin A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms. 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))-,Cefalexin,Cephalexin Dihydride,Cephalexin Hemihydrate,Cephalexin Hydrochloride,Cephalexin Monohydrate,Cephalexin Monohydrochloride,Cephalexin Monohydrochloride, Monohydrate,Cephalexin, (6R-(6alpha,7alpha(R*)))-Isomer,Cephalexin, (6R-(6alpha,7beta(S*)))-Isomer,Cephalexin, (6R-(6alpha,7beta))-Isomer,Cephalexin, Monosodium Salt,Cephalexin, Monosodium Salt, (6R-(6alpha,7beta))-Isomer,Ceporexine,Palitrex
D002515 Cephradine A semi-synthetic cephalosporin antibiotic. Anspor,Cefradine,Cephradine Dihydrate,Cephradine, Non-Stoichiometric Hydrate,Dexef,Kelsef,Maxisporin,Nicef,SQ-11436,Sefril,Septacef,Velocef,Velosef,Zeefra Gé,Cephradine, Non Stoichiometric Hydrate,Dihydrate, Cephradine,Non-Stoichiometric Hydrate Cephradine,SQ 11436,SQ11436
D004927 Escherichia coli Infections Infections with bacteria of the species ESCHERICHIA COLI. E coli Infections,E. coli Infection,Infections, E coli,Infections, Escherichia coli,E coli Infection,E. coli Infections,Escherichia coli Infection,Infection, E coli,Infection, E. coli,Infection, Escherichia coli
D005260 Female Females

Related Publications

J Rotschafer, and K Crossley, and D Zaske, and R Viste
January 1979, Infection,
J Rotschafer, and K Crossley, and D Zaske, and R Viste
October 1981, Acta urologica Belgica,
J Rotschafer, and K Crossley, and D Zaske, and R Viste
November 1983, Antimicrobial agents and chemotherapy,
J Rotschafer, and K Crossley, and D Zaske, and R Viste
July 2000, Clinical therapeutics,
J Rotschafer, and K Crossley, and D Zaske, and R Viste
June 1974, The Journal of infectious diseases,
J Rotschafer, and K Crossley, and D Zaske, and R Viste
January 1987, Urology,
J Rotschafer, and K Crossley, and D Zaske, and R Viste
February 1984, The Journal of pediatrics,
J Rotschafer, and K Crossley, and D Zaske, and R Viste
January 2001, Medical science monitor : international medical journal of experimental and clinical research,
J Rotschafer, and K Crossley, and D Zaske, and R Viste
September 1990, Antimicrobial agents and chemotherapy,
J Rotschafer, and K Crossley, and D Zaske, and R Viste
February 1983, European journal of clinical microbiology,
Copied contents to your clipboard!